Diagnostic exogenous probe strategy using ezetimibe-glucuronide effectively identifies metabolic dysfunction–associated steatohepatitis

DRUG METABOLISM AND DISPOSITION · Published 2026-06-29 · DOI 10.1016/j.dmd.2026.100351

Authors (29)

Dominique O. Farrera, Kayla L. Frost, Joseph L. Jilek, Paxton A. Sample, Jailyn M. Izu, Mina M. Alaaldin, Paige Lindberg, Max M. Maloney, David Rodrigues, Emi Yamaguchi, Sangwoo Ryu, Yi-An Bi, Mark A. West, Sumathy Mathialagan, Sarah Lazzaro, Brooke Rabe, Aiden-Hung P. Nguyen, Katherine Ho, Susie Messenger, Ahmad Omid Rahimi, Ryan Akhbari, Carolina Säll, Walter Klimecki, Mary F. Paine, Stephen H. Wright, Dean Billheimer, Geoffrey Block, Iman Ghaderi, Nathan J. Cherrington

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Farrera, D., Frost, K., Jilek, J., et al. (2026). Diagnostic exogenous probe strategy using ezetimibe-glucuronide effectively identifies metabolic dysfunction–associated steatohepatitis. DRUG METABOLISM AND DISPOSITION. https://doi.org/10.1016/j.dmd.2026.100351

Related articles